Mangalam Drugs And Organics Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.

Results View source PDF Explain this filing

MANGALAM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹48.43

prior close

₹48.33

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.5%-2.1% vs market

Pharmaceuticals peers, median of 154sector-0.7%-2.9% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+0.3

15m

-0.6

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6-1.5-2.1-0.7-2.9

Next day

-17.8-2.1-15.7-1.5-16.3

-25.0-2.0-23.0-2.0-23.0

-32.5-0.7-31.8-0.7-31.9

-39.3-1.2-38.1-0.9-38.4

-42.3-1.3-41.1-0.7-41.6

-48.0-2.0-46.0-1.1-46.9

15d

-48.1-4.4-43.6-2.5-45.6

-49.7-3.2-46.5-2.0-47.8

+1.6-11.8+13.4-9.1+10.7

-35.7-7.3-28.4-8.8-26.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mangalam Drugs And Organics Limited has submitted its financial results for the second quarter (Q2) of FY26, covering the period ended September 30, 2025, to the NSE. The filing announcement itself does not contain the detailed revenue, profit, or margin figures, which would be available in the actual results document. No auditor commentary, exceptional items, or restatement details are mentioned in this brief filing notice.

Likely market impact

This is a routine regulatory submission confirming that the company has met its listing obligation to file quarterly results on time. Shareholders and investors should look at the detailed results document to evaluate revenue growth, profitability, and margin trends before drawing any conclusions about the stock's direction.